December 2007 Volume 3, Issue 12
Volume 3, Issue 12 | December 2007
December 2007
In this Issue
Informatics

Free for all (students)
Accelrys makes SciTegic Pipeline Pilot Student Edition free to academic researchers
Schizophrenia data deal
Genizon Biosciences and NDEI to share samples, technologyAutomation & Instrumentation

One molecule at a time
Team-up of Agilent and BioNanomatrix focuses on nanoscale whole-genome imaging and analysis
WaferGen’s alpha dog
Pitt Med School tapped as alpha test site for WaferGen’s real-time PCR system
Xceed launches Strategic Collaborator program
Xceed has already committed to several other institutions under its Strategic Collaborator programGenomics & Proteomics

Band-aid for the brain?
Alzheimer’s drugs target symptoms not disease
On your mark, get set...
NextGen appoints new CEO and expands services into protein biomarker monitoring
RXi and Invitrogen: All quiet on the RNAi front
RXi Pharmaceutical and Invitrogen announced they have entered into an agreement for RXi to license on an exclusive basis second-generation RNAi technology from Invitrogen for designated target genes in all human therapeutic categories.Research & Development

Putting on a new spin
Amgen spins out Relypsa from newly acquired Ilypsa
Antisense approach to scars
Isis and Excaliard look to topical antisense drugs to treat scars and other fibrotic conditions
SRI vs. HIV
SRI in new contract with NIAID for preclinical services
Rosetta and NYU expand microRNA collaboration
Israel-Rosetta Genomics Ltd. and the New York University School of Medicine have expanded their collaboration to include congenital heart disease.
Gene Logic discovers new use for Pfizer drug
Gene Logic Inc. recently announced a collaboration milestone, triggered by the filing of a patent application for a new use of an existing Pfizer drug candidate to treat solid tumorsGlobal News

All that glitters
Nanoengineers mine tiny diamonds for drug delivery
GPC begins restructuring
Staff reductions of approximately 44 percent are in store for GPC Biotech AG after the recent announcement of a corporate restructuring plan
Allies against Alzheimer’s
Biogen Idec and Neurimmune to work on antibody-based treatment for AD

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe